Telix Pharmaceuticals (innovations) Pty Limited

This study tests a new drug (lutetium rosopatamab) that delivers radiation directly to prostate cancer cells. It is for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. The trial compares the new drug plus standard care versus s…

This early-stage study tests a radioactive drug called 131I-TLX101 given alongside standard treatment for people newly diagnosed with glioblastoma, an aggressive brain cancer. The main goal is to find a safe dose and check for side effects. About 12 adults who have had surgery fo…

This study tests a new drug, 177Lu-TLX250, which delivers radiation directly to kidney cancer cells that have a specific marker (CAIX). It is for adults with advanced clear cell kidney cancer that has come back or not responded to at least two prior treatments. The trial compares…

This study tests a new drug called TLX101-Tx, which delivers targeted radiation directly to brain cancer cells, combined with standard chemotherapy (lomustine) in adults whose glioblastoma has returned after initial treatment. The goal is to see if the combination helps control t…

This study tests whether combining two advanced scans (PSMA PET and MRI) is better than standard methods for finding prostate cancer in men with elevated PSA levels. About 204 men will get both scans and a biopsy to confirm results. The goal is to see if the combo scan reduces un…

This early-phase study tests a single dose of TLX090-Tx in 33 adults with advanced cancer that has spread to the bones, causing pain. The goal is to see if the drug is safe and can reduce pain. Participants must have tried other treatments without success.